Oksana Hamidi1. 1. Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
PURPOSE OF REVIEW: Metastatic pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with variable prognosis. This review highlights recent studies on outcomes and management of patients with metastatic PPGL. RECENT FINDINGS: Latest advances were made in identifying predictors of favorable outcomes of patients with metastatic PPGL. Recent studies evaluated the efficacy of tyrosine kinase inhibitors, high-specific-activity radiopharmaceuticals, and peptide receptors radionuclide therapy in treatment of metastatic disease. Moreover, ongoing studies are assessing the effects of hypoxia-inducible factor 2αα and heat shock protein 90 inhibitors as potential therapies. SUMMARY: Several active studies are evaluating the efficacy of systemic chemo, immuno, radiopharmaceutical, and peptide receptor radionuclide therapies to relieve local and adrenergic symptoms and provide survival benefit for patients with symptomatic and/or progressive advanced metastatic PPGL. Owing to rarity and wide-outcome variability, multidisciplinary team effort and personalized approach are central in caring for patients with metastatic PPGL.
PURPOSE OF REVIEW: Metastatic pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with variable prognosis. This review highlights recent studies on outcomes and management of patients with metastatic PPGL. RECENT FINDINGS: Latest advances were made in identifying predictors of favorable outcomes of patients with metastatic PPGL. Recent studies evaluated the efficacy of tyrosine kinase inhibitors, high-specific-activity radiopharmaceuticals, and peptide receptors radionuclide therapy in treatment of metastatic disease. Moreover, ongoing studies are assessing the effects of hypoxia-inducible factor 2αα and heat shock protein 90 inhibitors as potential therapies. SUMMARY: Several active studies are evaluating the efficacy of systemic chemo, immuno, radiopharmaceutical, and peptide receptor radionuclide therapies to relieve local and adrenergic symptoms and provide survival benefit for patients with symptomatic and/or progressive advanced metastatic PPGL. Owing to rarity and wide-outcome variability, multidisciplinary team effort and personalized approach are central in caring for patients with metastatic PPGL.
Authors: Hiren V Patel; Arnav Srivastava; Murray D Becker; Toni Beninato; Amanda M Laird; Eric A Singer Journal: Curr Urol Rep Date: 2021-01-06 Impact factor: 3.092
Authors: Thomas G Papathomas; Diederik P D Suurd; Alfred K Lam; Ronald R de Krijger; Karel Pacak; Arthur S Tischler; Menno R Vriens Journal: Endocr Pathol Date: 2021-01-12 Impact factor: 3.943
Authors: Kedar G Sharbidre; Ajaykumar C Morani; Mohd Zahid; Priya Bhosale; Chandana Lall; Isaac R Francis; Sadhna Verma Journal: Abdom Radiol (NY) Date: 2022-04-12
Authors: Sudhir Kumar Rai; Fernando Bril; Heather M Hatch; Yiling Xu; Laura Shelton; Srilaxmi Kalavalapalli; Arielle Click; Douglas Lee; Chris Beecher; Austin Kirby; Kimi Kong; Jose Trevino; Abhishek Jha; Shashank Jatav; Kriti Kriti; Soumya Luthra; Timothy J Garrett; Joy Guingab-Cagmat; Daniel Plant; Prodip Bose; Kenneth Cusi; Robert A Hromas; Arthur S Tischler; James F Powers; Priyanka Gupta; James Bibb; Felix Beuschlein; Mercedes Robledo; Bruna Calsina; Henri Timmers; David Taieb; Matthias Kroiss; Susan Richter; Katharina Langton; Graeme Eisenhofer; Raymond Bergeron; Karel Pacak; Sergei G Tevosian; Hans K Ghayee Journal: Metabolism Date: 2020-06-18 Impact factor: 13.934
Authors: Shatha Albattal; Meshael Alswailem; Yosra Moria; Hindi Al-Hindi; Majed Dasouki; Mohamed Abouelhoda; Hala Aba Alkhail; Entissar Alsuhaibani; Ali S Alzahrani Journal: Oncotarget Date: 2019-10-15